| Identification | Back Directory | [Name]
2-[4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid | [CAS]
516-50-7 | [Synonyms]
Tudcabil
Deoxycholyltaurine
Deoxytaurocholic Acid
Taurodeoxychloic Acid
Taurodesoxycholic Acid
Taurosulfodeoxycholic acid
Taurodeoxycholic Acid MaxSpec? Standard
N-(3a,12a-Dihydroxy-5-cholan-24-oyl)taurine
Taurodeoxycholic Acid
Discontinued See T009005
Taurodeoxychloic Acid Discontinued See T009005
N-(2-Sulfoethyl)-3α,12α-dihydroxy-5β-cholan-24-amide
2-[[(3a,5,12)-3,12-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic Acid
2-[[(3α,5β,12α)-3,12-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic acid
Ethanesulfonic acid, 2-[[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]amino]-
2-((R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid
2-[4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid | [Molecular Formula]
C26H45NO6S | [MOL File]
516-50-7.mol | [Molecular Weight]
499.7 |
| Chemical Properties | Back Directory | [Melting point ]
175-200 °C | [density ]
1.216±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated, Sonicated) | [form ]
Solid | [pka]
1.42±0.50(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. | [Definition]
ChEBI: A bile acid taurine conjugate of deoxycholic acid. | [in vivo]
Taurodeoxycholic acid (1.25-5 mg/kg, p.o., 6 days) ameliorates dextran sodium sulfate (DSS)-induced colitis in mice[9].
Taurodeoxycholic acid (Taurodeoxycholic acid form, 50 mg/kg; i.p.; once daliy for 34 d) prevents neuropathology and associated behavioral deficits in the 3-nitropropionic acid rat model of Huntington's disease (HD) [10].
Taurodeoxycholic acid (Taurodeoxycholic acid form, 500 mg/kg; s.c.; once every 3 d for 7 weeks) leads to a significant reduction in striatal neuropathology of the R6/2 transgenic HD mouse[11].
Taurodeoxycholic acid (0.5 mg/kg; i.v., once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[12].
| Animal Model: | A mouse colitis model (fed with 3% (w/v) DSS in drinking water for the first seven days and then switched to normal drinking water for an additional two days)[9] | | Dosage: | 1.25, 2.5, and 5 mg/kg | | Administration: | Oral gavage (p.o.), from day 3 to day 8, once a day | | Result: | Prevented loss of body weight, shortening of the colon, production of pro-inflammatory cytokines, infiltration of pro-inflammatory cells, and mucosal ulceration in the colon.
|
| Animal Model: | Huntington's disease model in mouse[10] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment | | Result: | Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions.
Significantly improved locomotor and sensorimotor deficits.
|
| Animal Model: | C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[12] | | Dosage: | 0.5 mg/kg | | Administration: | Intravenous injection, 30 min or 24 h after LPS injection | | Result: | Improved the survival rate of mice with sepsis.
Decreased liver and kidney damage in septic mice.
Ameliorated systemic inflammation and normalized blood pressure in septic mice.
|
| [IC 50]
Microbial Metabolite |
|
|